AI Portfolio Summary
In 2025 Q4, Merck & Co., Inc. maintained a portfolio of 13 distinct positions. Conversely, Merck & Co., Inc. completely exited their position in LAVA THERAPEUTICS NV.
Total Positions
13
Quarter
2025 Q4
Top Holding
PSNL (40.5%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-13 of 13
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PSNL
PERSONALIS INC
|
Unknown | 40.47% | 40.16% |
#1
Prev: #1
|
10.0 | no change | no change |
P
S
|
14,044,943 | $111,797,746 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRNA
MODERNA INC
|
Unknown | 24.64% | 26.15% |
#2
Prev: #2
|
9.9 | no change | no change |
P
S
|
2,308,190 | $68,068,523 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KYMR
KYMERA THERAPEU...
|
Unknown | 21.75% | 19.17% |
#3
Prev: #3
|
8.7 | no change | no change |
P
S
|
772,165 | $60,082,159 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
ENTRADA THERAPE...
|
—
|
Unknown | 6.47% | 4.43% |
#4
1
Prev: #5
|
2.6 | no change | no change |
P
S
|
1,739,768 | $17,884,815 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
EVAX
EVAXION BIOTECH...
|
Unknown | 2.10% | 2.00% |
#5
1
Prev: #6
|
0.8 | no change | no change |
P
S
|
1,214,126 | $5,791,381 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALEC
ALECTOR INC
|
Unknown | 2.00% | 4.60% |
#6
2
Prev: #4
|
0.8 | no change | no change |
P
S
|
3,545,719 | $5,531,322 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
STRO
SUTRO BIOPHARMA...
|
Unknown | 1.14% | 1.04% |
#7
Prev: #7
|
0.7 | -2,451,158 | -90.0% |
P
S
|
272,351 | $3,151,101 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
VIRIDIAN THERAP...
|
Unknown | 1.05% | 0.88% |
#8
Prev: #8
|
0.4 | no change | no change |
P
S
|
93,414 | $2,907,044 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XLO
XILIO THERAPEUT...
|
Unknown | 0.34% | 0.55% |
#9
1
Prev: #10
|
0.1 | no change | no change |
P
S
|
1,483,758 | $949,902 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CARM
CARISMA THERAPE...
|
Unknown | 0.02% | 0.18% |
#10
1
Prev: #11
|
0.0 | no change | no change |
P
S
|
1,473,240 | $63,349 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NEUP
NEUPHORIA THERA...
|
Unknown | 0.01% | 0.05% |
#11
1
Prev: #12
|
0.0 | no change | no change |
P
S
|
10,027 | $38,905 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
HURA
TUHURA BIOSCIEN...
|
Unknown | 0.00% | 0.02% |
#12
1
Prev: #13
|
0.0 | no change | no change |
P
S
|
13,950 | $10,556 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LVTX
LAVA THERAPEUTI...
|
Unknown | 0.00% | 0.79% |
Sold All 😨
(Was: #9) |
0.3 | -1,149,345 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-13 of 13 holdings